1	Changes in monocyte subsets can predict the risk of AAA and are surrogate markers
2	for AAA morphology in patients with late-stage disease
3	Short title: AAA, monocyte subsets, risk prediction, surrogate marker
4	Bianca Hamann ¹ , Anna Klimova ² , Marvin Kapalla ¹ , David M. Poitz ³ , Frieda Frank ¹ ,
5	Henning Morawietz ⁴ , Christian Reeps ^{1*} and Anja Hofmann ^{1*}
6	*contributed equally
7	¹ Division of Vascular and Endovascular Surgery, Department of Visceral, Thoracic and
8	Vascular Surgery, University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden
9	University of Technology, Germany;
10	² Institute for Medical Informatics and Biometry, Faculty of Medicine, TUD Dresden
11	University of Technology, Germany;
12	³ Institute for Clinical Chemistry and Laboratory Medicine; University Hospital and Medical
13	Faculty Carl Gustav Carus, TUD Dresden University of Technology, Germany;
14	⁴ Division of Vascular Endothelium and Microcirculation, Department of Medicine III,
15	University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden University of
16	Technology, Germany;
17	#Corresponding author:
18	Anja Hofmann, PhD
19	Division of Vascular and Endovascular Surgery
20	Department of Visceral-, Thoracic and Vascular Surgery
21	Faculty of Medicine and University Hospital Carl Gustav Carus
22	TUD Dresden University of Technology
23	Fetscherstraße 74
24	D-01307 Dresden, Germany
25	Email: anja.hofmann2@uniklinikum-dresden.de
26	
27	Word count: 3.343 (Excluding references, figure legends and table legends)
28	Word count abstract: 217

29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Graphical Abstract



35 Abstract

36 **Background** Monocytes play a pivotal role in pathology of abdominal aortic aneurysm (AAA) 37 and can display an immunophenotypic heterogeneity with functionally distinct subpopulations. 38 Alterations in monocyte subsets have been described in CVD, and some are associated with 39 cardiovascular risk, but their profile in AAA is poorly understood. Aim We aimed to 40 comprehensively define associations of circulating monocyte phenotypes with AAA risk and 41 AAA morphology. Methods Monocyte subsets (CD14++CD16-; CD14++/CD16+; 42 CD14+/CD16++) were analyzed in a prospective, observational study in patients with AAA 43 (n=34) and varicose veins (n=34) by using flow cytometry. **Results** Classical monocytes were 44 1.6-fold lower (P=0.001) in AAA, while intermediate and non-classical monocytes were 1.8 45 (P=0.019) and 1.9-fold (P=0.025) higher in AAA, respectively. The differences remained significant after adjusting for age, sex and peripheral artery disease. A lower proportion of 46 47 classical monocytes (HR: 0.73, P=0.002) and increases in intermediate (HR: 1.41, P=0.006) 48 and non-classical monocytes (HR: 1.54, P=0.030) were associated with a higher risk of AAA. 49 Non-classical monocytes showed an inverse correlation with AAA diameter (Pearson 50 correlation =-0.64, P=0.001) and AAA volume (Pearson correlation =-0.50, P=0.003). 51 Conclusion The present study revealed age- and sex-independent shifts in monocytes, all of 52 which were associated with risk of AAA disease. Non-classical monocytes were inversely 53 correlated with AAA diameter and volume and thus may be surrogate markers for AAA 54 morphology.

55 Non-standard abbreviations and acronyms

- 56 AAA, abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; ARBs, angiotensin
- 57 receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery
- 58 disease; CAS, carotid artery stenosis; CCB, calcium channel blocker; CVD, cardiovascular
- 59 disease; Hb, hemoglobin; HDL, high-density lipoprotein cholesterol; HF, heart failure; LDL,
- 60 low-density lipoprotein cholesterol; PAD, peripheral artery disease; T2D, Type 2 diabetes
- 61 mellitus; **TC**, total cholesterol

62 What's new?

- Classical monocytes are lower in patients with late-stage AAA. 63 •
- 64 • Non-classical monocytes showed the strongest increase in AAA disease.
- A reduction in classical monocytes is associated with increased risk of AAA. 65 •
- An increase in non-classical and intermediate monocytes is associated with an increased 66 risk of AAA. 67
- 68 Lowering in non-classical monocytes may be a surrogate marker for AAA morphology, 69 particlarly AAA volume.
- 70 Intermediate monocytes showed a positive correlation with the thickness of the 71 intraluminal thrombus.
- 72

73 What are the clinical implications?

- 74

- - The increase in non-classical monocytes could be a novel surrogate marker for AAA •
- 75 volume, which could be useful when AAA diameter is insufficient or to monitor a 76 saccular AAA, as there is a weaker correlation between diameter and risk of rupture in this type of AAA. 77
- 78 The decrease in classical monocytes could be a useful surrogate marker for AAA • 79 volume and provide additional information on AAA diameter.
- 80 Monocyte shifts and their association with AAA disease may be relevant for the • 81 diagnosis of AAA and should be verified in larger cohorts.
- 82 The mechanisms behind the decrease in classical monocytes and the increase in • intermediate and non-classical subsets should be investigated in further *in vitro* studies 83 as they offer therapeutic potential. 84

85 Introduction

86 Abdominal aortic aneurysm (AAA) is a life-threatening condition with high mortality rates. 87 Main pathological features are inflammation with increased local cytokine production, extracellular matrix degradation, oxidative stress and the loss of smooth muscle cells.¹ The 88 89 only effective treatment is surgical elimination of the AAA. Pharmacological treatments are 90 still lacking, emphasizing the need to define the pathomechanisms that contribute to the 91 initiation and progression of the disease. Inflammatory cells in AAA comprise monocytes, 92 macrophages, neutrophils, mast cells, natural killer (NK) cells, T and B cells and dendritic cells.² Monocytes are recruited at sites of inflammation where they differentiate into 93 macrophages.³ Monocytes exist in subsets, which differ in morphology, function and cell 94 surface marker (e.g. chemokine receptors) expression. Three distinct subsets were 95 96 distinguished in humans based on the expression of the the LPS-receptor CD14 and the Fcy 97 receptor CD16: classical (CD14++CD16-), non-classical (CD14+CD16++) and intermediate (CD14++CD16+) monocytes.⁴ Classical monocytes (CD14++CD16-) secrete large amounts 98 99 of pro-inflammatory cytokines and promote angiogenesis, wound healing and coagulation, demonstrating their importance in tissue repair.³ In contrast, CD16-expressing cells may 100 101 secrete pro-inflammatory cytokines, have a high antigen-presenting capacity and the ability to migrate into subendothelial spaces and atherosclerotic lesions.⁴ These cells include 102 103 intermediate monocytes (CD14++CD16+), that secrete pro-inflammatory cytokines and accumulate in chronic inflammatory diseases.^{3,5,6} Intermediate subsets are predictive for 104 cardiovascular disease⁴ and are associated, for example, with susceptibility to plaque 105 106 vulnerability³. CD16+ subsets are elevated in patients with AAA⁷ and a recently published 107 study showed that only intermediate monocytes (CD14++CD16+) were elevated in AAA compared to healthy individuals and patients with PAD⁸. Interestingly, CD14++CD16+ and D-108

dimer proved to be suitable diagnostic markers for AAA while elevated concentrations of these
 subsets were able to predict rapid growing AAA.⁸

111 Non-classical monocytes have low expression of CD14 (CD14+) and secrete pro- and anti-112 inflammatory cytokines. These monocytes have phagocytic properties to remove cell debris 113 and are important for patrolling the vascular endothelium and controlling vascular integrity. Most likely, they are involved in the resolution of inflammation.³ However, it should be noted 114 115 that a CD14-low subset may promote neovascularization and destabilization of lesions, while 116 their accumulation in ischemic tissue may have beneficial effects.⁴ 117 Although an increase in intermediate subsets has been demonstrated in AAA, it is still under 118 debate whether the three subgroups correlate with AAA diameter, AAA volume, and thickness 119 of the intraluminal thrombus as the main morphologic features of AAA and could be useful 120 surrogate markers. In addition, there is no information whether any of these monocyte subsets 121 can predict end-stage AAA, when most patients with AAA are diagnosed. Here, we aimed to 122 comprehensively define associations of circulating monocyte phenotypes with AAA risk and

123 AAA morphology.

124 Materials and Methods

125 Study Design

Monocyte subpopulations were determined in an observational study in electively treated AAA 126 127 patients and patients with varicose veins who served as controls. Due to the observational 128 nature of the study, no sample size or power calculation was performed, according to the STROBE guidelines.⁹ Patients were treated in the Department of Visceral, Thoracic and 129 Vascular Surgery between December 2020 and June 2024. The diagnostic criteria for varicose 130 131 patients included venous reflux assessed by duplex ultrasound and signs of chronic venous insufficiency according to the CEAP classification.¹⁰ Inclusion criteria were age over 50 years 132 133 and no known history of arterial disease, T2D and infectious diseases. Patients with 134 thrombophlebitis were excluded. Inclusion criteria for AAA patients were a diameter of the 135 infrarenal aorta of more than 40 mm, a rapidly growing AAA with more than 10 mm 136 progression per year or a symptomatic AAA. The study was approved by the ethics committee 137 of the Technische Universität Dresden (EK 151042017). Informed consent was obtained from 138 all study participants.

139 **Outcome Variables**

140 Counts of each monocyte subset were defined as the primary outcome variable in the 141 multivariate logistic regression, while AAA disease was defined as the outcome variable in the 142 hazard ratio analysis.

143

144 Clinical Parameters

Serum low-density (LDL) and high-density (HDL) lipoprotein, total cholesterol (TC), triglycerides, non-fasting glucose, hemoglobin (Hb), leukocyte, and C-reactive protein (CRP) concentrations were analyzed in the Institute for Clinical Chemistry and Laboratory Medicine at the TU Dresden using standard laboratory methods. Due to the lack of data on blood

chemistry or medical therapies, the number of analyzed patients varies in each group. Cardiovascular risk factors, comorbidities, and prescribed medical therapies were evaluated retrospectively. Hypertension, type 2 diabetes (T2D), heart failure (HF), peripheral artery disease (PAD), and carotid artery stenosis (CAS) were defined by a past documented history of diagnosis or any treatment for these diseases. CAD was defined by a history of myocardial infarction, angina, or treatment for CAD. Smoking was defined as any history of smoking and sex was self-reported.

156

157 Analysis of AAA Diameter and AAA Morphology

158 The aortic diameter, maximal intraluminal thrombus depth and aortic volumes were determined 159 as described previously.¹¹ In brief, aortic diameter was assessed by computed tomography 160 angiography by measuring the distance between the outer adventitia (outer-to-outer-edge) by a 161 single trained observer. Thickness of the ILT was determined in the arterial phase on CT scans 162 following multiplanar reconstruction. The aorta was scanned in an axial position in 1 mm 163 sections. The thickness of the ILT was assessed at the largest distance from the inner surface 164 of the lumen to the outer aortic wall. The AAA volume was measured by two trained people using the automatic segmentation model of the IMPAX EE R20 software (Agfa HealthCare, 165 166 Mortsel, Belgium). The aorta was scanned with contrast media in the arterial phase in 1 mm 167 sections. The outer wall of the aneurysm and the true lumen were selected manually every 168 6 mm in the transverse plane. The starting point of the measurement was defined as the cranial 169 end of the aneurysm with a diameter greater than 30 mm. The measurement ended caudal to 170 the dilation or at the aortic bifurcation. Non-recognized areas were cropped manually. The 171 volume of AAA is given in cm³. The ILT was included in the total AAA volume measurement 172 but was not specifically tagged for segmentation.

174 Blood Samples and Flow Cytometry

175 Non-fasting venous blood was collected pre-operatively between 2020 and 2024 in 9 mL S-Monovette EDTA (Sarstedt, Nürmbrecht, Germany). Monocyte subpopulations were 176 177 analyzed using flow cytometry. Cells were stained for 10 min using the following antibody 178 cocktail: CD45-FITC (HI-30, Thermo Fisher Scientific, Darmstadt, Germany), CD16-179 PerCP710 (CB16, Thermo Fisher Scientific Darmstadt, Germany) and CD14-PE (MoP9, BD 180 Biosciences, Heidelberg, Germnay). Isotype controls were prepared to ensure selectivity of the 181 antibodies. Afterwards, erythrocytes were lysed by the addition of FACS lysing solution (BD 182 Biosciences, Heidelberg, Germnay) for 10 min. Data acquisition was performed on LSR 183 Fortessa (BD Biosciences, Heidelberg, Germnay) and LSR II (BD Biosciences, Heidelberg, Germnay). Data analysis was performed using FlowJoTM Software (Version 10, BD 184 185 Biosciences, Heidelberg, Germnay). First, debris was excluded by applying SSC and FSC, and 186 events with low FSC and SSC signals were omitted. Before cell aggregates were excluded from 187 the analysis, expression of CD45 against the SSC signal was used to select the monocyte 188 population for further analysis. Finally, classical (CD14++CD16-), non-classical 189 (CD14+CD16++) and intermediate (CD14++CD16+) monocytes were determined according 190 to their expression of CD14 and CD16 (Supplementary Figure 1).

191

192 Statistics

Graph Pad Prism 10.0 (GraphPad Software, Inc., La Jolla, CA, USA) and R Core Team (2021) R: A Language and Environment for Statistical Computing software (R Foundation for Statistical Computing, Vienna/Austria) were used for statistical analysis. A *P*-value ≤ 0.05 was considered significant. Outliers were tested with the Grubbs outlier test and normality distribution with the D'Agostino and Pearson test. According to the result of the normal distribution test, Mann–Whitney U or unpaired t-test were used to compare AAA and varicose

199 vein patients. Data are shown as box plots with individual values or as scatter dot plots, as 200 indicated in the figure legends. Correlational analysis was done using Pearson correlation (r_P). 201 Weighted linear regression was performed for variable selection, to assess the influence of age, 202 sex, smoking, hypertension, T2D, CAD, PAD, CRP, HDL-, LDL cholesterol, triglyceride, 203 hemoglobin, leukocyte count, AAA diameter, thickness of the ILT and prescription of insulin, 204 diuretics, statins, ACE, CCB, ARBs, β-blocker, ASA and therapeutic anticoagulation. As some 205 comorbidities strongly influence each other, only age and sex were included in the final 206 analysis. In addition, PAD was included in the multivariate analysis as patients already served as a control group in numerous studies.⁸ Data were analyzed by multivariate logistic regression 207 208 using each of the monocyte subgroups as a indepedent variable for the presence of AAA 209 disease. Subgroup concentrations were log transformed, and the effect of risk factors was 210 compared with patients in whom the risk factor was not present.

211 **Results**

212 Patient Characteristics

The comparison of AAA and venous vein patient's revealed that the AAA group was significantly older and comprised more male patients than varicose vein controls. As expected, both groups differed in their prevalence of cardiovascular risk factors and prescribed pharmacotherapy. A detailed list of risk factors and pharmacotherapy is given in **Table 1**.

217

218 Phenotypic Heterogeneity of Monocyte Subsets in AAA Patients

219 In the present study, significants shifts in monocyte subsets were observed in AAA patients 220 compared to controls with varicose veins. In patients with an AAA, there were 1.6-fold lower 221 (P=0.001) counts for classical monocytes and 1.9-fold (P=0.025) and 1.8-fold (P=0.019) 222 higher counts for non-classical monocytes and intermediates, respectively (Figure 1). To 223 determine which of the patients' risk factors and comorbidities influenced the subgroups the 224 most, we performed a linear weighted regression. We found that classical monocytes are 225 relatively robust, since they are barely affected by any of the investigated comorbidities and 226 risk factors (Supplementary Table 1). In non-classical monocytes, PAD was associated with 227 an increase, and T2D as well as hypertension were associated with a decrease in this subset 228 (Supplementary Table 2). Intermediate monocytes were strongly influenced by the presence 229 of T2D, while sex and hypertension were associated with a decrease in this subset 230 (Supplementary Table 3). All the investigated comorbidities and risk factors were seen to 231 highly confound each other. We therefore performed a logistic regression analysis and chose 232 age, sex and PAD for adjustment to analyze whether these factors influence the observed 233 differences between varicose veins and AAA. After adjusting for age, sex and PAD the 234 observed decrease in classical monocytes (P=0.001) and increase in non-classical monocytes 235 (P=0.040) in AAA patients remained significant (**Table 2**).

236 Monocyte Subsets, AAA Risk and Associations with AAA Morphology

Hazard ratios were calculated to test whether differences in monocyte subgroups lead to an increased risk of AAA disease. A reduced number of classical monocytes was associated with an increased risk of AAA (P=0.002). Furthermore, increased levels of non-classical (P=0.030)

- and intermediate monocytes (*P*=0.006) led to a higher risk for AAA disease (**Table 3**).
- 241

242 Monocytes and Correlations with AAA Morphology

243 A correlational analysis was performed to test whether the different monocyte subgroups 244 correlate with the morphology of the AAA and can therefore serve as surrogate markers. 245 Classical monocytes showed a trend to increase with AAA diameter (Figure 2A), while no 246 correlations with AAA volume or ILT thickness were found (Table 4). Conversely, non-247 classical monocytes decreased with increasing AAA diameter (r_P=-0.64, P<0.001) and 248 increasing AAA volume (r_P=-0.50, P=0.003) (Figure 2B,C). Intermediate monocytes showed 249 a trend towards a positive association with maximum depth of the ILT ($r_P=0.32$, P=0.067) 250 (Figure 2D). Table 4 provides an extended overview of the tested correlations.

251 Discussion

252 Monocytes are important inflammatory mediators in cardiovascular disease and also in AAA 253 as a particular CVD. Depending on the expression of their surface markers, monocytes are 254 classified into different subgroups that have different functions. Knowledge about their expression patterns may contribute to the understanding of specific disease mechanisms as 255 256 these cells migrate into inflamed tissue and differentiate into macrophages. Moreover, this 257 would allow the identification of patients at high risk and provide useful surrogate markers for 258 AAA morphology. Although an increase in intermediate subsets has been demonstrated in 259 AAA⁸, nothing is known whether these subsets correlate with AAA diameter, AAA volume 260 and intraluminal thrombus as main morphologic features of AAA. Determination of surrogate 261 markers that correlate with the maximum AAA diameter is of great interest, as the AAA diameter is the most important marker for decisions on surgical therapy.¹² Furthermore, there 262 263 is no information on whether any of these subgroups can predict the risk of having AAA.

264 The present study showed a lower count of classical monocytes (CD14++CD16-) and higher counts of intermediate (CD14++CD16+) and non-classical monocytes (CD14+CD16++) in 265 266 patients with AAA. Our data are, at least in part, supported by previously published studies.^{7,8} 267 The decreased proportion of classical monocytes could be explained by findings in mice after induction of acute myocardial infarction. In the first phase, CD14+CD16- monocytes 268 accumulate early at the site of injury to clear necrotic debris and promote healing of the 269 270 damaged tissue. CD14+CD16++ dominate in the second phase and promote healing through the accumulation of myofibroblasts, angiogenesis and collagen deposition.¹³ The data herein 271 272 eventually underline an imbalance between both subsets in patients with AAA towards 273 intermediate subsets that promote fibrotic remodeling in the AAA wall. While non-classical 274 monocytes remain in the bloodstream, classical monocytes could transmigrate through the

endothelium into the vessel wall.¹⁴ This could be a possible explanation for the depletion of the
classic monocytes, which could be due to an increased migration into the AAA.

Non-classical monocytes are the most inflammatory subset but also show patrolling function.¹⁵ 277 Studies in patients with CAD¹⁶ and subclinical atherosclerosis demonstrated increased non-278 classical subsets¹⁷ and therefore coincidence the data of the present study. Herein, a higher 279 280 count of non-classical was found in AAA, which is different to data previously published by Klopf et al.⁸ Most often, patients with PAD served as controls in biomarker studies in AAA.¹⁸ 281 PAD is one of the most common initial manifestations of $T2D^{19}$ and T2D itself is inversely 282 associated with AAA disease.²⁰ It might be of speculation that a confounding of protective and 283 284 adverse effects could occur.

285 To further understand the link between AAA risk and blood monocytes, we analyzed whether 286 a specific subtype of monocyte was associated with increased risk of having AAA disease. We 287 were able to show that a lower proportion of classical monocytes was associated with a higher 288 risk of AAA, while an increase in non-classical and intermediate monocytes was associated 289 with an increased risk of AAA. It could be that the increase in intermediate and non-classical subsets occurs at the expense of classical monocytes. Similar results were demonstrated in 290 patients with T2D.²¹ Intermediate monocytes have been demonstrated to be an independent 291 predictor of cardiovascular events in patients with atherosclerotic diseases.²² Similar results 292 were obtained for non-classical monocytes.²² The increased risk might be explained by the 293 proinflammatory role of intermediate and non-classical monocytes.²² Interestingly, the 294 295 percentage of classical monocytes might be a protective factor for major adverse outcomes in coronary artery disease.²³ Classical monocytes are known to be phagocytic but have no 296 inflammatory potential.¹⁵ Given their protective role, the decrease in AAA and their association 297 298 with AAA risk might be a hint to a loss of their function.

299 The higher percentage of non-classical, CD14+CD16++ monocytes was inversely associated 300 with the AAA diameter and AAA volume. Analyzing the AAA volume has the advantage of including the morphology of the aneurysm.²⁴ AAA volume can be useful when the diameter 301 302 fails or for monitoring saccular AAA, since there is a weaker correlation between increased diameter and rupture risk in this type of AAA.²⁵ Finally, AAA volume might be a better 303 predictor for AAA growth.²⁶ A negative correlation between non-classical, CD14+CD16++ 304 monocytes with the intima-media-thickness was shown in patients with carotid artery stenosis²⁷ 305 306 and in peripheral artery disease where non-classical subsets decreased with the severity⁵. CD14+CD16++ monocytes (or Ly-6C^{lo} in mice) are involved in healing of the ischemic 307 308 myocardium and they initiate the differentiation towards M2 macrophages, known to be 309 involved in tissue repair. It might be of speculation, but the inverse relationship could be 310 explained by temporal patterns and lack of their protective and healing functions²⁷, although 311 they are higher in patients with AAA. Another possibility that could explain the inverse 312 relationship between AAA diameter and non-classical monocytes is that non-classical 313 monocytes migrate into the AAA, i.e. as the diameter increases, more cells migrate in and their 314 concentration in the blood decreases. In addition, the patients examined here are in the final stage of the disease and exhibit the typical degeneration of the AAA wall.^{18,28} 315

316 The majority of AAA are covered by an intraluminal thrombus (ILT). The ILT contains fibrin, inflammatory cells, platelets and red blood cells and affects growth and rupture of the AAA.^{29,30} 317 318 Herein, intermediate (CD14++CD16+) subsets tended to correlate with the thickness of the 319 ILT in AAA-patients. Intermediate monocytes are capable of antigen presentation, secreting pro-inflammatory cytokines and to regulate immune responses.³¹ It has been demonstrated that 320 321 intermediate monocytes are present in the ILT but in lower amounts than in peripheral blood of AAA patients.³² The positive association could reflect the inflammatory nature of the ILT 322 323 or also cells that are released by the ILT.

324 Overall, the present study showed age- and sex-independent shifts in classical, non-classical 325 and intermediate subsets in AAA, suggesting disease-specific mechanisms. An decrease in 326 classical monocytes and the increases in intermediate and non-classical monocytes were 327 associated with risk for having AAA. The number of non-classical monocytes correlated 328 inversely with AAA diameter and AAA volume and could therefore be a useful surrogate 329 marker for AAA morphology, beyond the AAA diameter. Especially the lowering in 330 phagocytic classical monocytes and the increase in non-classical monocytes should be 331 considered in future studies.

332 Limitations

333 The present study is a descriptive, observational study on a very small cohort of patients. 334 Varicose vein patients were used as a control group and their limitation is their different 335 comorbidity and risk factor profile. The relativley small number of patients included and the 336 large number of confounding factors may have influenced the results. Analyzing patients in whom the risk factors have been adjusted prior, e.g. in a case-control study, could minimize 337 338 these effects. Furthermore, the results obtained here do not allow to establish a causal 339 relationship between the different monocyte subsets and the development of AAA which is due 340 to the study design. Finally, the main discrepancy when comparing data from flow cytometry 341 with the present study is the pre-selection of cells, the declaration of subgroups based on the 342 expression of CD14 and CD16 and the gating strategy in flow cytometry.

343

344 Acknowledgement

345 Flow cytometry measurement and analysis was done at the Flow Cytometry Core Facility at

- 346 TU Dresden, University of Technology. We would like to thank Dr Anne Gompf, Head of the
- 347 Flow Cytometry Core Facility, for her excellent technical experience.

348 **Figures**



350 Figure 1: Monocyte Subsets in Patients with AAA and Varicose Vein Controls. Non-351 fasting venous-blood was collected and the relative frequency of the individual monocyte subpopulations was determined by flow cytometry. A, classical (CD14++CD16-), B, non-352 353 classical (CD14+CD16++) and C, intermediate (CD14++CD16+) monocytes. All data are 354 shown as boxplots with individual values. Outliers were identified using the Grubb's outlier 355 test and one patient in each group was excluded from all further analysis. A, Unpaired t-test, 356 B-C, Mann-Whitney U test.





Figure 2: Correlation of Monocyte Subsets and AAA Morphology. Monocyte subsets were 358 359 analyzed using flow cytometry and are given as % of total monocytes. The data were 360 logarithmically transformed and analyzed for correlations with the morphology of the AAA. 361 Correlation of A, classical monocytes with AAA diameter, B, AAA diameter and non-classical 362 monocytes, C, non-classical monocytes and AAA volume and D, ILT and intermediate monocytes. Statistics: Grubb's outlier test was used to identify outliers. One AAA patient was 363 364 identified as an outlier and excluded from all further analysis. Correlational analysis was done 365 using the Pearson correlation. rP, Pearson rank correlation coefficient.

366 Tables

 Table 1: Clinical Characteristics in Patients with Abdominal Aortic Aneurysm (AAA)
 367 and Venous Vein varicose. Blood was taken in the non-fasted state. Reference values for the 368 369 corresponding blood parameters are given in the table. Reference values for LDL and total 370 cholesterol (TC) are based on the European Society of Cardiology (ESC) recommendations. 371 Reference values for fasting glucose were excluded due to the withdrawal in the non-fasted 372 state. Statistics: All data are presented as median with minimum and maximum values. 373 Comparison of continuous data was done using the Mann-Whitney U test or t-test. Discrete 374 data were analyzed by Chi-Square test. For t test (a) t-statistic is reported, Mann-Whitney (b) 375 U statistics and Chi-square (c) X^2 is reported. Abbreviations: ACE, angiotensin-converting 376 enzyme; ARBs, angiotensin receptor blocker; BMI, body mass index; ASA, acetylsalicylic 377 acid; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density 378 lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; T2D, type 2 379 diabetes mellitus; TIA, transient ischemic attack.

Observational study									
	Varicosis eAAA <i>P</i> -value Statistics								
Baseline demographics									
n included	33	33							
Age – years, mean \pm SD	62.79 ± 8.15	70.39 ± 9.41	<0.001 ^a	t=3.51					
Sex, male:female, % male	20:13, 61	30:3, 91	0.0041°	X ² =8.25					

Hematology						
Hemoglobin – mmol/L, mean	Hemoglobin – mmol/L, mean 8.99 ± 0.73 9.01 ± 1.10 0.948^{a}					
± SD, n	32	33				
Reference v	alues 8.60 – 12.10) mmol/L				
Leukocytes – GPt/L, mean ±	6.83 ± 1.48	7.64 ± 1.68	0.046 ^a	t=2.04		
SD, n	32	33				
Reference values 3.8 – 9.8 GPt/I	_					
Cardiovascular risk factors						
LDL cholesterol – mmol/L,	4.18 ± 1.50	3.28 ± 1.36	0.014 ^a	t=2.53		
mean \pm SD, n	31	33				
Reference values	<1.40 mmol/L for	people with very	-high risk			
HDL cholesterol – mmol/L,	1.63	1.28	0.015 ^b	U=331.00		
median with range, n	(1.00 – 2.62)	(0.75 – 1.98)				
	31	33				
Reference values >0.9	Reference values >0.90 mmol/L for men and >1.10 mmol/L for women					
Total cholesterol – mmol/L,	4.57 ± 1.37	3.52 ± 1.55	0.006 ^a	t=0.85		
mean \pm SD, n	31	33				
Reference values <4.00 mmol/L						

Triglycerides – mmol/L,	1.18	1.20	0.582 ^b	U=455.50
median with range, n	(0.43 – 3.88)	(0.52 – 3.59)		
	31	32		
Refe	rence values 0.35	– 1.70 mmol/L		
Blood glucose – mmol/L,	5.37	5.94	0.004 ^b	U=238.50
median with range, n	(4.30 - 6.81)	(4.69 – 11.33)		
	28	30		
Reference	value only for fast	ting glucose possi	ble	
CRP – mg/L, median with	1.30	2.65	0.049 ^b	U=353.50
range, n	(0.50 – 21.30)	(0.60 – 16.80)		
	31	31		
]	Reference values -	<5.0 mg/L		
Smoking, yes:no – %	6:27, 18	23:10, 70	<0.001°	X ² =17.78
Hypertension, yes:no – %	11:22, 33	30:3, 91	<0.001°	X²=23.24
CAD, yes:no – %	0:33, 0	10:23, 30	0.001 ^c	X ² =11.79
HF, yes:no – %	1:32, 3	10:23, 30	0.003 ^c	X ² =8.84
CAS, yes:no – %	0:33, 0	7:26, 21	0.005°	X ² =7.83
PAD, yes:no – %	0:33, 0	8:25, 24	0.003 ^c	X ² =9.10
T2D, yes:no – %	0:33, 0	11:22, 33	<0.001°	X ² =13.20

It is made available une	der a <mark>CC-B</mark> Ý	4.0 International	license .
--------------------------	---------------------------	-------------------	-----------

BMI – kg/m^2 , median with	27.20	27.25	0.677 ^b	U=511.50
range, n	(21.20 - 40.70)	(20.30 - 38.01)		
	33	33		
Pharmacological therapies				
Statins, yes:no – %	3:29, 9	24:9, 73	<0.001°	X ² =26.85
ACE inhibitors, yes:no – %	3:29, 9	15:18, 45	0.001°	X ² =10.56
ARB, yes:no – %	4:28, 13	13:20, 39	0.014 ^c	X ² =6.08
CCB, yes:no – %	2:30, 6	13:20, 39	0.002 ^c	X ² =10.05
ASA, yes:no – %	2:30, 6	25:8, 76	<0.001°	X ² =32.32
b-blocker, yes:no – %	4:28, 13	17:16, 52	<0.001 ^c	X ² =11.31
Anticoagulation, yes:no – %	6:26, 19	3:30, 9	0.260 ^c	X²=1.27
Antiplatelet, yes:no – %	1:31, 3	3:30, 9	0.317 ^c	X ² =1.00
Diuretics, yes:no – %	4:28, 13	9:24, 27	0.137 ^c	X ² =1.49
T2D treatment, yes:no – %	0:32, 0	11:22, 33	<0.001°	X ² =12.84
Insulin, yes:no – %	0:32, 0	2:31, 6	0.157 ^c	X ² =2.00

382 Table 2: Differences in Monocyte Subsets after Adjusting to Age, Sex and PAD. Monocyte

383 subsets were analyzed using flow cytometry and monocytes are given in % of total monocytes. 384 Data were analyzed by multivariate logistic regression using each of the monocyte subgroups 385 as a diagnostic variable for the presence of AAA disease. The monocyte subgroups were 386 logarithmically transformed, and data were analyzed by multivariate logistic regression using 387 the corresponding subset as a predictor variable. The effects of each risk factor were compared 388 with patients in whom the risk factor was not present (ref=none). The odds ratio (OR) refers to 389 the relative increase in risk of AAA disease as the percentage of the subgroup increases on the 390 logarithmic scale. For sex, ORs refer to men and reference values refer to women. AAA 391 diameter and age show the increase per unit (year and mm, respectively). Unadjusted values 392 were obtained by pairwise comparison of each variable listed in the table with the outcome of 393 having an AAA. Adjusted values were analyzed by holding the effects of the other variables 394 constant and assuming an increase in the monocyte subset on the logarithmic scale. 395 Abbreviations: OR, odds ratio.

Variable	Unadjusted OR	<i>P</i> -value	Adjusted OR	<i>P</i> -value	
	[95% CI]		[95% CI]		
classical monocytes [log10]					
Group (ref=varicosis)	0.973 [0.958, 0.987]	<0.001	0.968 [0.949, 0.987]	0.001	
Age (years)	0.999 [0.998, 1.000]	0.076	1.000 [0.999, 1.001]	0.950	
Sex (ref=female)	1.001 [0.982, 1.021]	0.895	1.014 [0.994, 1.035]	0.160	

PAD (ref=none)	0.987 [0.963, 1.012]	0.308	1.004 [0.980, 1.029]	0.754				
	non-classical m	onocytes [lo	og10]					
Group	1.504 [1.019, 2.220]	0.040	1.760 [1.058, 2.928]	0.030				
(ref=varicosis)								
Age (years)	1.002 [0.981, 1.024]	0.830	0.988 [0.964, 1.012]	0.331				
Sex (ref=female)	1.024 [0.635, 1.652]	0.921	0.784 [0.462, 1.330]	0.360				
PAD (ref=none)	1.283 [0.697, 2.360]	0.417	1.026 [0.537, 1.960]	0.937				
	intermediate M	Ionocytes [le	og10]					
Group	1.674 [0.988, 2.836]	0.055	1.940 [0.987, 3.814]	0.054				
(ref=varicosis)								
Age (years)	1.024 [0.996, 1.053]	0.091	1.007 [0.975, 1.040]	0.680				
Sex (ref=female)	0.709 [0.375, 1.343]	0.287	0.563 [0.279, 1.136]	0.107				
PAD (ref=none)	1.203 [0.527, 2.745]	0.656	0.857 [0.363, 2.024]	0.721				

399 Table 3: Hazard Ratios of Monocyte Subsets and AAA risk. Monocyte subsets were

400 analyzed using flow cytometry and monocytes are given in % of total monocytes. Logistic

- 401 regression was used to obtain hazard ratio of incident AAA per one unit increase in monocytes
- 402 subsets on log scale.

	Hazard Ratio [95% CI]	<i>P</i> -value
Classical monocytes	0.726 [0.584, 0.874]	0.002
Intermediate monocytes	1.412 [1.123, 1.846]	0.006
Non-classical monocytes	1.537 [1.068, 2.354]	0.030

404 Table 4: Summary of Correlations Between Monocyte Subsets and AAA Morphology.

Monocyte subsets were analyzed using flow cytometry and monocyte subsets are given in %
of total monocytes. Data were log transformed. Correlational analysis was performed using
Pearson correlation. Outliers were identified using Grubb's outlier test and excluded from
further analysis. Abbreviations: AAA, Abdominal aortic aneurysm, ILT, Intraluminal
thrombus, **r**_P, Pearson's rank correlation coefficient.

410

	classical mo	onocytes	non-classical		intermediate	
			monocytes		monocytes	
	r _P	<i>P</i> -value	r _P	<i>P</i> -value	r _P	<i>P</i> -value
AAA	0.32	0.069	-0.64	<0.001	-0.20	0.265
diameter						
ILT	-0.21	0.23	0.19	0.298	0.32	0.067
AAA	0.27	0.13	-0.50	0.003	-0.13	0.481
volume						

- 412 References
- 413 Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and 1. 414 macrophages in abdominal aortic aneurysm. Nat Rev Cardiol. 2017;14:457-471. doi: 415 10.1038/nrcardio.2017.52
- 416 2. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of 417 abdominal aortic aneurysm. Front Immunol. 2022;13:989933. doi: 418 10.3389/fimmu.2022.989933
- 419 3. Ruder AV, Wetzels SMW, Temmerman L, Biessen EAL, Goossens P. Monocyte 420 heterogeneity in cardiovascular disease. Cardiovasc Res. 2023;119:2033-2045. doi: 421 10.1093/cvr/cvad069
- Hristov M, Leyendecker T, Schuhmann C, Hundelshausen P von, Heussen N, Kehmeier 422 4. 423 E, Krötz F, Sohn H-Y, Klauss V, Weber C. Circulating monocyte subsets and 424 cardiovascular risk factors in coronary artery disease. Thromb Haemost. 2010;104:412-425 414. doi: 10.1160/TH10-01-0069
- 426 5. Wildgruber M, Aschenbrenner T, Wendorff H, Czubba M, Glinzer A, Haller B, Schiemann M, Zimmermann A, Berger H, Eckstein H-H, Meier R, Wohlgemuth WA, 427 428 Libby P, Zernecke A. The "Intermediate" CD14++CD16+ monocyte subset increases in 429 severe peripheral artery disease in humans. Sci Rep. 2016;6:39483. doi: 430 10.1038/srep39483
- 431 van der Laan AM, Hirsch A, Robbers LFHJ, Nijveldt R, Lommerse I, Delewi R, van der 6. 432 Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC, 433 Voermans C, van der Schoot CE, Piek JJ. A proinflammatory monocyte response is 434 associated with myocardial injury and impaired functional outcome in patients with ST-435 segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart 436 J. 2012;163:57-65.e2. doi: 10.1016/j.ahj.2011.09.002
- 437 Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, Pane B, 7. 438 Spallarossa P, Altieri P, Fabbi P, Sambuceti G, Palombo D. CD16(+) monocyte subsets 439 are increased in large abdominal aortic aneurysms and are differentially related with 440 circulating and cell-associated biochemical and inflammatory biomarkers. Dis Markers. 441 2013;34:131-142. doi: 10.1155/2013/836849
- 442 Klopf J, Zagrapan B, Brandau A, Lechenauer P, Candussi CJ, Rossi P, Celem ND, Ziegler 8. 443 M, Fuchs L, Hayden H, Krenn CG, Eilenberg W, Neumayer C, Brostjan C. Circulating 444 monocyte populations as biomarker for abdominal aortic aneurysms: a single-center 445 retrospective cohort study. Front Immunol. 2024;15:1418625. doi: 446 10.3389/fimmu.2024.1418625
- 447 9. Vandenbroucke JP, Elm E von, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole 448 C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in 449 Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 450 10.1371/journal.pmed.0040297
- 451 10. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, Bush RL, Blebea J, 452 Carpentier PH, Maeseneer M de, Gasparis A, Labropoulos N, Marston WA, Rafetto J, 453 Santiago F, Shortell C, Uhl JF, Urbanek T, van Rij A, Eklof B, Gloviczki P, Kistner R, 454 Lawrence P, Moneta G, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP 455 classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 456 2020;8:342-352. doi: 10.1016/j.jvsv.2019.12.075
- 457 11. Hamann B, Klimova A, Klotz F, Frank F, Jänichen C, Kapalla M, Sabarstinski P, Wolk S, 458 Morawietz H, Poitz DM, Hofmann A, Reeps C. Regulation of CD163 Receptor in Patients 459 with Abdominal Aortic Aneurysm and Associations with Antioxidant Enzymes HO-1 and 460 NQO1. Antioxidants (Basel). 2023;12. doi: 10.3390/antiox12040947

- 461 12. Wanhainen A, Mani K, Golledge J. Surrogate Markers of Abdominal Aortic Aneurysm 462 Progression. Arterioscler Thromb Vasc Biol. 2016;36:236-244. doi: 463 10.1161/ATVBAHA.115.306538
- 464 13. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, 465 Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 466 467 2007:204:3037-3047. doi: 10.1084/jem.20070885
- 14. Feinstein MJ, Dovle MF, Stein JH, Sitlani CM, Fohner AE, Huber SA, Landay AL, 468 469 Heckbert SR, Rice K, Kronmal RA, Hedrick C, Manichaikul A, McNamara C, Rich S, 470 Tracy RP, Olson NC, Psaty BM, Delaney JAC. Nonclassical Monocytes 471 (CD14dimCD16+) Are Associated With Carotid Intima-Media Thickness Progression for 472 Men but Not Women: The Multi-Ethnic Study of Atherosclerosis-Brief Report. 473 Arterioscler Thromb Vasc Biol. 2021;41:1810-1817. doi: 474 10.1161/ATVBAHA.120.315886
- 475 15. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. 476 Non-Classical monocytes display inflammatory features: Validation in Sepsis and 477 Systemic Lupus Erythematous. Sci Rep. 2015;5:13886. doi: 10.1038/srep13886
- 478 16. Urbanski K, Ludew D, Filip G, Filip M, Sagan A, Szczepaniak P, Grudzien G, Sadowski 479 J, Jasiewicz-Honkisz B, Sliwa T, Kapelak B, McGinnigle E, Mikolajczyk T, Guzik TJ. 480 CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in 481 patients with coronary artery disease. Thromb Haemost. 2017;117:971-980. doi: 482 10.1160/TH16-08-0614
- 483 17. Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn J-F, 484 Veyrie N, Rizkalla S, Fridman W-H, Sautès-Fridman C, Clément K, Cremer I. 485 CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: 486 relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 487 2011;31:2322-2330. doi: 10.1161/ATVBAHA.111.230979
- 488 18. Hofmann A, Khorzom Y, Klimova A, Wolk S, Busch A, Sabarstinski P, Müglich M, 489 Egorov D, Kopaliani I, Poitz DM, Kapalla M, Hamann B, Frank F, Jänichen C, Brunssen 490 C, Morawietz H, Reeps C. Associations of Tissue and Soluble LOX-1 with Human 491 Abdominal Aortic Aneurysm. JAm Heart Assoc. 2023;12:e027537. doi: 492 10.1161/JAHA.122.027537
- 493 19. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, 494 Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of 495 cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 496 2015;3:105-113. doi: 10.1016/S2213-8587(14)70219-0
- 497 20. Tsai C-L, Lin C-L, Wu Y-Y, Shieh D-C, Sung F-C, Kao C-H. Advanced complicated 498 diabetes mellitus is associated with a reduced risk of thoracic and abdominal aortic 499 aneurysm rupture: a population-based cohort study. Diabetes Metab Res Rev. 500 2015;31:190-197. doi: 10.1002/dmrr.2585
- 501 21. Julla J-B, Girard D, Diedisheim M, Saulnier P-J, Tran Vuong B, Blériot C, Carcarino E, 502 Keizer J de, Orliaguet L, Nemazanyy I, Potier C, Khider K, Tonui DC, Ejlalmanesh T, 503 Ballaire R, Mambu Mambueni H, Germain S, Gaborit B, Vidal-Trécan T, Riveline J-P, 504 Garchon H-J, Fenaille F, Lemoine S, Carlier A, Castelli F, Potier L, Masson D, Roussel 505 R, Vandiedonck C, Hadjadj S, Alzaid F, Gautier J-F, Venteclef N. Blood Monocyte 506 Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. Circ Res. 507 2024;134:189-202. doi: 10.1161/CIRCRESAHA.123.322757
- 508 22. Hristov M, Weber C. Monocyte Subsets in Cardiovascular Disease: A Biomarker 509 Perspective. Thromb Haemost. 2024. doi: 10.1055/a-2348-5697

- 510 23. Dregoesc MI, Tigu AB, Bekkering S, van der Heijden CDCC, Rodwell L, Bolboacă SD, 511 Joosten LAB, Netea MG, Riksen NP, Iancu AC. Intermediate monocytes are associated 512 with the first major adverse cardiovascular event in patients with stable coronary artery 513 disease. Int J Cardiol. 2024;400:131780. doi: 10.1016/j.ijcard.2024.131780
- 514 24. Kitagawa A, Mastracci TM, Allmen R von, Powell JT. The role of diameter versus volume 515 as the best prognostic measurement of abdominal aortic aneurysms. J Vasc Surg. 516 2013;58:258-265. doi: 10.1016/j.jvs.2013.05.001
- 25. Vaitėnas G, Mosenko V, Račytė A, Medelis K, Skrebūnas A, Baltrūnas T. Abdominal 517 518 Aortic Aneurysm Diameter versus Volume: A Systematic Review. Biomedicines. 519 2023:11. doi: 10.3390/biomedicines11030941
- 520 26. Lindquist Liljeqvist M, Hultgren R, Gasser TC, Roy J. Volume growth of abdominal aortic 521 aneurysms correlates with baseline volume and increasing finite element analysis-derived 522 rupture risk. J Vasc Surg. 2016;63:1434-1442.e3. doi: 10.1016/j.jvs.2015.11.051
- 523 27. Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, Nilsson 524 J, Björkbacka H. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ 525 Cardiovasc Genet. 2012;5:122-131. doi: 10.1161/CIRCGENETICS.111.960385
- 526 28. Hofmann A, Müglich M, Wolk S, Khorzom Y, Sabarstinski P, Kopaliani I, Egorov D, 527 Horn F, Brunssen C, Giebe S, Hamann B, Deussen A, Morawietz H, Poitz DM, Reeps C. Induction of Heme Oxygenase-1 Is Linked to the Severity of Disease in Human 528 529 Abdominal Aneurysm. J Am Heart Assoc. 2021;10:e022747. Aortic doi: 530 10.1161/JAHA.121.022747
- 531 29. Koole D, Zandvoort HJA, Schoneveld A, Vink A, Vos JA, van den Hoogen LL, Vries J-532 PPM de, Pasterkamp G, Moll FL, van Herwaarden JA. Intraluminal abdominal aortic 533 aneurysm thrombus is associated with disruption of wall integrity. J Vasc Surg. 534 2013;57:77-83. doi: 10.1016/j.jvs.2012.07.003
- 535 30. Cameron SJ, Russell HM, Owens AP. Antithrombotic therapy in abdominal aortic 536 aneurysm: beneficial or detrimental? Blood. 2018;132:2619-2628. doi: 10.1182/blood-2017-08-743237 537
- 538 31. Williams H, Mack C, Baraz R, Marimuthu R, Naralashetty S, Li S, Medbury H. Monocyte 539 Differentiation and Heterogeneity: Inter-Subset and Interindividual Differences. Int J Mol 540 Sci. 2023;24. doi: 10.3390/ijms24108757
- 541 32. Sagan A, Mrowiecki W, Mikolajczyk TP, Urbanski K, Siedlinski M, Nosalski R, Korbut 542 R, Guzik TJ. Local inflammation is associated with aortic thrombus formation in 543 abdominal aortic aneurysms. Relationship to clinical risk factors. Thromb Haemost. 544 2012;108:812-823. doi: 10.1160/TH12-05-0339
- 545